Trending...
- Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
- OpenSSL Corporation Advisory Committees' Elections 2026: Results Announcement
- Mecpow M1: A Safe & Affordable Laser Engraver Built for Home DIY Beginners
$RENB Collaboration with $NVDA to Employ NVIDIA AI Tech with Established GEDi CUBE as a Paradigm Shift for Early Disease Detection
LOS ANGELES - PennZone -- Developing AI and Biotechnology Platforms for Early Diagnosis, Better-Targeted Treatments and Drug Discovery.
Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI).
$15 Million in New Equity Committed to accelerate Focus on Revolutionizing Healthcare via the Company's Established Strategies.
2025 Shareholder Update Issued from CEO.
Plans to Attend American Association for Cancer Research (AACR), The First and Largest Cancer Research Organization, Annual Meeting in April, 2025.
Funding Approval of LUMINA Minimal Residual Disease Detection Platform for Lung Cancer Harnessing Multi-omics Biomarkers and AI.
Entered Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection.
Plans to Establish the Renovaro GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's Certified AI Healthcare Cloud Solutions.
Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
$15 Million in New Equity Committed
On February 26th RENB announced that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.
More on The PennZone
David Weinstein, Chief Executive Officer of Renovaro, commented, "We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery."
Shareholder Letter and Corporate Update
On January 7th RENB issued a letter to shareholders from Chief Executive Officer David Weinstein. The letter contained the following commentary:
Dear Shareholders,
We have identified three areas as mission critical for building the point of care cancer detection, personalized therapy and vaccine business are: we need to acquire large amounts of data, build the business of clinical decision support for oncologists, and monetize our AI though building and licensing predictive models for drug repurposing and our cancer vaccine. We are meeting these three challenges through the acquisition of Predictive Oncology.
RENB recently signed a binding letter of intent to acquire Predictive Oncology (Stock Symbol: POAI) that will provide with a tremendous company-owned database consisting of 150,000 frozen / live tumor samples, 20 years of drug response data, 40,000 FFPE tissue blocks, 200,000 pathology slides and digital library, and a fully certified CLIA laboratory. RENB plans to commercialize Predictive's clinical support test that assists oncologists in selecting the best therapy for their patients, and deploy their multi-omic AI system for drug discovery known as PEDAL (Patient-centric Discovery by Active Learning), a platform that combines AI technology, drug response data, and a large biobank of tumor samples to predict how different tumors will respond to various drugs.
When RENB acquired GEDiCube, the rationale was that these two business segments were synergistic. This remains a core value proposition but for synergies to materialize requires structured collaboration between the two verticals: AI cancer detection and genetically enhanced cancer vaccines. There are two business developments that RENB is pursuing.
Identifying a whole genome sequencer that can serve as the front end of RENB point of care cancer detection platform.
GEDiCube to deploy its AI/ML analysis to discover more genes and factors that can be deployed in RENB Dendritic Cancer Cell Vaccine (DCCV). Incorporating these new discoveries into RENB patent filings will build shareholder value by ringfencing the DCCV platform and providing the ability to partner or license specific cancer applications. This has the potential to enhance the core three elements RENB infuses into DCCV now, allowing it to become specific for cancer types, and ultimately be available as an off the shelf solution. In the future this could facilitate early cancer detection in a doctor's office followed by the treatment of a patient with our vaccine. To gain exposure for our DCCV and generate business development RENB will be attending the American Association for Cancer Research (AACR), the first and largest cancer research organization, Annual Meeting in April 2025.
More on The PennZone
To make its AI/ML powered early cancer detection tests a reality, RENB requires two vital components: the latest superpods to achieve the speed necessary to run trillions of calculations, and critical data and sample sets. RENB announced in late December 2024, a strategic collaboration with Nebul (www.nebul.com) that will provide that power. Additionally, Nebul is focused on healthcare and is ISO certified. The company has received a grant for the Lumina project that aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for non-small cell lung cancer (NSCLC). This project provides RENB with 100 samples for immediate analysis followed by an additional 200 samples as they are generated and provides critical data.
Maurice van Tilburg, RENB Chairman, has decided to join full time as the CEO of the AL/ML subsidiary, GEDiCube. Renovaro management, including Mr. van Tilburg.
Further strengthening the management team, RENB has brought Nathen Fuentes on board as CFO. On the corporate front, NASDAQ notified that the company is now in good standing.
For more information on $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc. (Stock Symbol: RENB)
Contact Person: David Weinstein, CEO
Company Websites: www.renovarobio.com and https://www.compasslivemedia.com/renb/
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI).
$15 Million in New Equity Committed to accelerate Focus on Revolutionizing Healthcare via the Company's Established Strategies.
2025 Shareholder Update Issued from CEO.
Plans to Attend American Association for Cancer Research (AACR), The First and Largest Cancer Research Organization, Annual Meeting in April, 2025.
Funding Approval of LUMINA Minimal Residual Disease Detection Platform for Lung Cancer Harnessing Multi-omics Biomarkers and AI.
Entered Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection.
Plans to Establish the Renovaro GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's Certified AI Healthcare Cloud Solutions.
Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
$15 Million in New Equity Committed
On February 26th RENB announced that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.
More on The PennZone
- Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
- Primeindexer Google indexing platform launched by SEO Danmark APS
- Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
- Talentica Announces Winners of Multi-Agent Hackathon 2026
- Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth
David Weinstein, Chief Executive Officer of Renovaro, commented, "We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery."
Shareholder Letter and Corporate Update
On January 7th RENB issued a letter to shareholders from Chief Executive Officer David Weinstein. The letter contained the following commentary:
Dear Shareholders,
We have identified three areas as mission critical for building the point of care cancer detection, personalized therapy and vaccine business are: we need to acquire large amounts of data, build the business of clinical decision support for oncologists, and monetize our AI though building and licensing predictive models for drug repurposing and our cancer vaccine. We are meeting these three challenges through the acquisition of Predictive Oncology.
RENB recently signed a binding letter of intent to acquire Predictive Oncology (Stock Symbol: POAI) that will provide with a tremendous company-owned database consisting of 150,000 frozen / live tumor samples, 20 years of drug response data, 40,000 FFPE tissue blocks, 200,000 pathology slides and digital library, and a fully certified CLIA laboratory. RENB plans to commercialize Predictive's clinical support test that assists oncologists in selecting the best therapy for their patients, and deploy their multi-omic AI system for drug discovery known as PEDAL (Patient-centric Discovery by Active Learning), a platform that combines AI technology, drug response data, and a large biobank of tumor samples to predict how different tumors will respond to various drugs.
When RENB acquired GEDiCube, the rationale was that these two business segments were synergistic. This remains a core value proposition but for synergies to materialize requires structured collaboration between the two verticals: AI cancer detection and genetically enhanced cancer vaccines. There are two business developments that RENB is pursuing.
Identifying a whole genome sequencer that can serve as the front end of RENB point of care cancer detection platform.
GEDiCube to deploy its AI/ML analysis to discover more genes and factors that can be deployed in RENB Dendritic Cancer Cell Vaccine (DCCV). Incorporating these new discoveries into RENB patent filings will build shareholder value by ringfencing the DCCV platform and providing the ability to partner or license specific cancer applications. This has the potential to enhance the core three elements RENB infuses into DCCV now, allowing it to become specific for cancer types, and ultimately be available as an off the shelf solution. In the future this could facilitate early cancer detection in a doctor's office followed by the treatment of a patient with our vaccine. To gain exposure for our DCCV and generate business development RENB will be attending the American Association for Cancer Research (AACR), the first and largest cancer research organization, Annual Meeting in April 2025.
More on The PennZone
- Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
- Vesica Health Receives FDA Breakthrough Device Designation for AssureMDx
- Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract
- Cancun All Inclusive is ready for Spring Break 2026 with new Resorts, Exclusive Deals, activities and more!
- 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies
To make its AI/ML powered early cancer detection tests a reality, RENB requires two vital components: the latest superpods to achieve the speed necessary to run trillions of calculations, and critical data and sample sets. RENB announced in late December 2024, a strategic collaboration with Nebul (www.nebul.com) that will provide that power. Additionally, Nebul is focused on healthcare and is ISO certified. The company has received a grant for the Lumina project that aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for non-small cell lung cancer (NSCLC). This project provides RENB with 100 samples for immediate analysis followed by an additional 200 samples as they are generated and provides critical data.
Maurice van Tilburg, RENB Chairman, has decided to join full time as the CEO of the AL/ML subsidiary, GEDiCube. Renovaro management, including Mr. van Tilburg.
Further strengthening the management team, RENB has brought Nathen Fuentes on board as CFO. On the corporate front, NASDAQ notified that the company is now in good standing.
For more information on $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc. (Stock Symbol: RENB)
Contact Person: David Weinstein, CEO
Company Websites: www.renovarobio.com and https://www.compasslivemedia.com/renb/
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
Filed Under: Business
0 Comments
Latest on The PennZone
- Josh Stout "The Western Project"
- Open House Momentum Builds at Heritage at South Brunswick
- A Celebration of Visibility, Voice and Excellence: The 57th NAACP Image Awards Golf Invitational, Presented by Wells Fargo, A PGD Global Production
- TopDogTours Expands Award-Winning Walking Tours in Philadelphia with Immersive Experiences
- Athens in Spring: A Culinary City Break That Rivals Paris and Copenhagen
- ClearSight Therapeutics Signs LOI with Covalent Medical for $60M Multi-Channel OTC Eye Care Partnership
- Jayne Williams Joins Century Fasteners Corp. Sales and Business Development Team
- Lord of the Rings Star Orlando Bloom To Host Special Experience at FAN EXPO Philadelphia
- Rocket Fibre Services Growing Customer Base With netElastic Networking Software
- Cummings Graduate Institute for Behavioral Health Studies Honors New Doctor of Behavioral Health Graduates
- IDpack v4 Launches: A Major Evolution in Cloud-Based ID Card Issuance
- Corey Lakins Set to Launch Glow Your Influence, a Podcast Spotlighting Women Leaders
- CCHR Says Psychiatry's Admission on Antidepressant Withdrawal Comes Far Too Late
- 505 Plumbing, Heating & Cooling Launches in Albuquerque, Bringing a Customer-First Approach to Home Services
- As AI.com Sells For Record $70 Million, Attention Now Turns To ArtificialIntelligence.com
- AOW Event Sponsored By The Stanglwirt Resort a renowned five-star Austrian wellness destination
- Average US gambler spends $210 per month in 2026
- 10X Recruitment Launches Operator-Led Executive Search for Behavioral Health and Legal Leaders
- Integris Composites developing armor for military in Arctic Circle
- Caraline Skincare's Gentle Glow Cleansing Oil Named Finalist for Best Face Cleanser at the 2026 CertClean Clean Beauty Awards